z-logo
Premium
A randomized controlled comparison of the efficacy of Dead Sea salt balneophototherapy vs. narrowband ultraviolet B monotherapy for chronic plaque psoriasis
Author(s) -
Dawe R.S.,
Yule S.,
Cameron H.,
Moseley H.,
Ibbotson S.H.,
Ferguson J.
Publication year - 2005
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.2005.06663.x
Subject(s) - psoriasis , medicine , plaque psoriasis , erythema , dermatology , population , environmental health
Summary Background  Dead Sea (DS) salt solution soaks are used in combination with narrowband ultraviolet B (NB‐UVB) to treat psoriasis in many centres, particularly in continental Europe. No previously published controlled study has assessed DS salt + NB‐UVB balneophototherapy. Objectives  To compare DS salt balneophototherapy with NB‐UVB monotherapy for chronic plaque psoriasis. Methods  Sixty patients with chronic plaque psoriasis participated in this paired, controlled study, with pretreatment DS salt soaks randomly allocated to each participant's right or left study limb. Psoriasis severity was assessed with a Scaling, Erythema and Induration score by a blinded observer. Assessments were weekly during the therapy course, and thereafter 8‐weekly until relapse or for up to 1 year after clearance. Results  The mean area under the psoriasis severity–time curves during treatment was not detectably lower with DS salt balneophototherapy than with NB‐UVB monotherapy ( P  = 0·099). The psoriasis severity score fell slightly more from beginning to end of courses with DS salt balneophototherapy than with NB‐UVB monotherapy ( P  = 0·019). There was no detectable difference in times to relapse. Conclusions  In this population the addition of pretreatment DS salt soaks to NB‐UVB did not result in a clinically important improvement in clearance of psoriasis.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here